This site is intended for healthcare professionals only

DiabetesontheNet Logo
×
News
Share this article
Share on facebook
Share on twitter
Share on email
Share on print

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Composite of cardiovascular death or hospitalisation for heart failure significantly reduced by 21% with empagliflozin compared to placebo.
Empagliflozin and HFpEF

The EMPEROR-Preserved trial explored the effect of the SGLT2 inhibitor empagliflozin in people living with heart failure with preserved ejection fraction (HFpEF), a condition which to date has had no compelling evidence-based interventions to reduce morbidity and mortality. After a median follow-up of 26 months, the primary endpoint (a composite of cardiovascular death or hospitalisation for HF) was significantly reduced by 21% with empagliflozin compared to placebo (absolute risk reduction, 3.3%; number needed to treat, 30). This was mainly driven by a significant reduction in hospitalisation for HF, as there were no statistically significant reductions in cardiovascular or all-cause death. Empagliflozin is the first therapeutic agent to robustly demonstrate statistically and clinically significant benefits in people living with HFpEF. These results should change clinical practice promptly given that SGLT2 inhibitors are already in widespread clinical use.

Click here to read Kevin Fernando’s discussion of the results in Diabetes Distilled.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.